Haitao Wang1, Bo Yang2, Xiaohua Chi3, Lili Cai4, Ruili Yu5, Hongli Zhu2, Shuai Tuo6, Feng Zhang7, Xuanchi Wang8, Yang Yang2, Xiaoxiong Wu9, Songwei Li9, Xuechun Lu10. 1. Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China; Department of Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China. 2. Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China. 3. Department of Pharmacy, the Second Artillery General Hospital, Beijing, China. 4. Department of Geriatric Laboratory Medicine, Chinese PLA General Hospital, Beijing, China. 5. Institute of Otorhinolaryngology, Chinese PLA General Hospital, Beijing, China. 6. Department of Medicine, Chinese PLA No. 202 Hospital, Shenyang, Liaoning, China. 7. Institute of Genomics, Chinese Academy of Sciences, Beijing, China. 8. Department of Oncology, Dandong Second Hospital, Shenyang, Liaoning, China. 9. Department of Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China. 10. Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China. Electronic address: luxuechun@126.com.
Abstract
PURPOSE: Elderly acute myelocytic leukemia (AML) patients have limited treatment options because they poorly tolerate standard-dose chemotherapy. The present article describes our experience with ultra-low-dose decitabine combined with infusion of autologous cytokine-induced killer (CIK) cells for 2 elderly patients with myelodysplastic syndrome-transformed AML. METHODS: Decitabine (10 mg) was given on days 1 to 5, and CIK cells on day 14 with 2 to 8 × 10(9) cells per infusion. FINDINGS: The therapeutic regimen resulted in marked hematologic recovery and was associated with better than expected survival in both cases. IMPLICATIONS: Our experience suggests that the combination therapy is safe and effective for elderly patients with myelodysplastic syndrome-transformed AML.
PURPOSE: Elderly acute myelocytic leukemia (AML) patients have limited treatment options because they poorly tolerate standard-dose chemotherapy. The present article describes our experience with ultra-low-dose decitabine combined with infusion of autologous cytokine-induced killer (CIK) cells for 2 elderly patients with myelodysplastic syndrome-transformed AML. METHODS:Decitabine (10 mg) was given on days 1 to 5, and CIK cells on day 14 with 2 to 8 × 10(9) cells per infusion. FINDINGS: The therapeutic regimen resulted in marked hematologic recovery and was associated with better than expected survival in both cases. IMPLICATIONS: Our experience suggests that the combination therapy is safe and effective for elderly patients with myelodysplastic syndrome-transformed AML.